Form 4: UNITED THERAPEUTICS Executive Sells Shares
Insider Transaction (Form 4)
Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on August 20, 2026.
Summary
- Option exercise/conversion: acquired 2,690 Common Stock at $146.03 ($392,821) on August 20, 2026; holds 47,862 after (Direct).
- Option exercise/conversion: acquired 5,610 Common Stock at $146.03 ($819,228) on August 20, 2026; holds 53,472 after (Direct).
- Open-market sale: disposed of 2,690 Common Stock at $524.15 ($1,409,964) on August 20, 2026; holds 50,782 after (Direct).
- Open-market sale: disposed of 502 Common Stock at $520.03 ($261,057) on August 20, 2026; holds 50,280 after (Direct).
- Open-market sale: disposed of 1,819 Common Stock at $521.04 ($947,773) on August 20, 2026; holds 48,461 after (Direct).
- Open-market sale: disposed of 787 Common Stock at $522.00 ($410,817) on August 20, 2026; holds 47,674 after (Direct).
- Open-market sale: disposed of 850 Common Stock at $522.78 ($444,366) on August 20, 2026; holds 46,824 after (Direct).
- Open-market sale: disposed of 192 Common Stock at $523.69 ($100,548) on August 20, 2026; holds 46,632 after (Direct).
- Open-market sale: disposed of 940 Common Stock at $525.25 ($493,735) on August 20, 2026; holds 45,692 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $526.38 ($210,554) on August 20, 2026; holds 45,292 after (Direct).
- Open-market sale: disposed of 120 Common Stock at $527.21 ($63,265) on August 20, 2026; holds 45,172 after (Direct).
- Option exercise/conversion: disposed of 2,690 Stock Option on August 20, 2026 (Direct).
- Option exercise/conversion: disposed of 5,610 Stock Option on August 20, 2026; holds 64,140 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,342,079 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul A Mahon — Officer (EVP & GENERAL COUNSEL)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Option exercise/conversion | Common Stock | 2,690 | $146 | $392.8K | 47,862 |
| 2026-08-20 | Option exercise/conversion | Common Stock | 5,610 | $146 | $819.2K | 53,472 |
| 2026-08-20 | Open-market sale | Common Stock | 2,690 | $524 | $1.4M | 50,782 |
| 2026-08-20 | Open-market sale | Common Stock | 502 | $520 | $261.1K | 50,280 |
| 2026-08-20 | Open-market sale | Common Stock | 1,819 | $521 | $947.8K | 48,461 |
| 2026-08-20 | Open-market sale | Common Stock | 787 | $522 | $410.8K | 47,674 |
| 2026-08-20 | Open-market sale | Common Stock | 850 | $523 | $444.4K | 46,824 |
| 2026-08-20 | Open-market sale | Common Stock | 192 | $524 | $100.5K | 46,632 |
| 2026-08-20 | Open-market sale | Common Stock | 940 | $525 | $493.7K | 45,692 |
| 2026-08-20 | Open-market sale | Common Stock | 400 | $526 | $210.6K | 45,292 |
| 2026-08-20 | Open-market sale | Common Stock | 120 | $527 | $63.3K | 45,172 |
| 2026-08-20 | Option exercise/conversion | Stock Option | 2,690 | — | — | 0 |
| 2026-08-20 | Option exercise/conversion | Stock Option | 5,610 | — | — | 64,140 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Option exercise/conversion (2,690 shares) |
| 2026-08-20 | Option exercise/conversion (5,610 shares) |
| 2026-08-20 | Open-market sale (2,690 shares) |
| 2026-08-20 | Open-market sale (502 shares) |
| 2026-08-20 | Open-market sale (1,819 shares) |
| 2026-08-20 | Open-market sale (787 shares) |
| 2026-08-20 | Open-market sale (850 shares) |
| 2026-08-20 | Open-market sale (192 shares) |
| 2026-08-20 | Open-market sale (940 shares) |
| 2026-08-20 | Open-market sale (400 shares) |
| 2026-08-20 | Open-market sale (120 shares) |
| 2026-08-20 | Option exercise/conversion (2,690 shares) |
| 2026-08-20 | Option exercise/conversion (5,610 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.